Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 1.00 |
| ▸ | SCD | O00767 | 7/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | CLK1 | P49759 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753691 | 0.89 | LRRK2 (1.00) | LRRK2SCDKMT2AMEN1NPC1 | |
| SCHEMBL16554294 | 0.89 | SCD (1.00) | LRRK2SCDKMT2AMEN1NPC1 | |
| SCHEMBL21753712 | 0.88 | LRRK2 (1.00) | LRRK2SCDKMT2AMEN1KDM4E | |
| SCHEMBL21753705 | 0.87 | LRRK2 (1.00) | LRRK2SCDKMT2ANPC1RAB9A | |
| SCHEMBL18425966 | 0.85 | SCD (0.78) | LRRK2SCDKMT2AMEN1NPC1 | |
| SCHEMBL31243 | 0.85 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL21753710 | 0.85 | LRRK2 (1.00) | LRRK2SCDKMT2AMEN1NPC1 | |
| SCHEMBL21753719 | 0.85 | LRRK2 (1.00) | LRRK2SCDNPC1RAB9AALDH1A1 | |
| SCHEMBL21753698 | 0.85 | LRRK2 (1.00) | LRRK2SCDKMT2AMEN1RAB9A | |
| SCHEMBL21753709 | 0.84 | LRRK2 (1.00) | LRRK2SCDKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912678-B2 | LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2024-02-27 | — | — | US | claimed |
| EP-3842422-B1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2022-09-07 | — | — | EP | claimed |
| US-20210323936-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2021-10-21 | — | — | US | claimed |
| EP-3842422-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Cientificas (ES) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039110-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2020-02-27 | — | — | WO | claimed |
| EP-3827665-B1 | MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2025-02-19 | — | — | EP | disclosed |
| US-11912678-B2 | LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2024-02-27 | — | — | US | disclosed |
| US-20230025843-A1 | MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-01-26 | — | — | US | disclosed |
| EP-3842422-B1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2022-09-07 | — | — | EP | disclosed |
| US-20210323936-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2021-10-21 | — | — | US | disclosed |
| EP-3842422-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Cientificas (ES) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021105182-A1 | MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-06-03 | — | — | WO | disclosed |
| EP-3827665-A1 | MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020039110-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323936-A1 | LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | LRRK2, PARK7, SNCA | LRRK2 1/4885SCD 2604/4885KMT2A 250/4885 |
| US-11912678-B2 | LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases | LRRK2, PARK7, SNCA | LRRK2 1/4885SCD 2604/4885KMT2A 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.